Search

Search Results

1. MFN2 Protein Regulates Cisplatin Sensitivity in Non-Small Cell Lung Cancer by Regulating Mitochondrial Autophagy

   This work was aimed to explore the mechanism of Mfn2 protein dependent cisplatin sensitivity in non-small cell lung cancer (NSCLC) by regulating...

   Hao Liu, Chaoqun Wu, ... Talaiguli **renbaike in Pharmaceutical Chemistry Journal

   Article 10 May 2023
   

2. Synthesis of Myrtucommulone D: A Selective Inhibitor of Tyrosyl-DNA Phosphodiesterase 2 Promoting Drug Resistance Reversal in Lung Cancer Cells

   Chemoresistance has emerged as a critical barrier in the treatment of lung cancer. The recently discovered DNA repair enzyme, tyrosyl-DNA...

   Yu Zhang, Long-Gao **ao, ... Zhen Wang in Revista Brasileira de Farmacognosia

   Article 05 January 2024
   

3. Alvopem^® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance

   Background

   Lung cancer is the leading cause of cancer deaths worldwide in both men and women, and non-small cell lung cancer (NSCLC) accounts for the...

   Sharareh Seifi, Babak Salimi, ... Adnan Khosravi in Journal of Pharmaceutical Policy and Practice

   Article Open access 25 January 2023

4. TNF receptor 2 knockout mouse had reduced lung cancer growth and schizophrenia-like behavior through a decrease in TrkB-dependent BDNF level

   The relationship between schizophrenia (SCZ) and cancer development remains controversial. Based on the disease-gene association platform, it has...

   In Jun Yeo, Ji Eun Yu, ... ** Tae Hong in Archives of Pharmacal Research

   Article Open access 09 April 2024
   

5. CD48-expressing non-small-cell lung cancer cells are susceptible to natural killer cell–mediated cytotoxicity

   The susceptibility of cancer cells to natural killer (NK) cell–mediated cytotoxicity depends on the balance of activating and inhibitory ligands...

   Eun Jae Park, Hye Won Jun, ... Sang-Bae Han in Archives of Pharmacal Research

   Article 14 December 2021
   

6. Anti-angiogenesis revisited: resha** the treatment landscape of advanced non-small cell lung cancer

   Although anti-angiogenic agents have been of limited use in the treatment of non-small cell lung cancer (NSCLC) until recently, further roles for the...

   Sun Ha Choi, Seung Soo Yoo, ... Jae Yong Park in Archives of Pharmacal Research

   Article 21 April 2022
   

7. Mahanimbine Suppresses the Proliferation of Lung Cancer A549 Cells Via Inducing Intrinsic Apoptotic Pathway

   Mahanimbine is a carbazole alkaloid that has been identified and isolated from several members of the Rutaceae family. Previous studies have...

   Gen Hu, ** Pu, ... **ao Zou in Revista Brasileira de Farmacognosia

   Article 02 March 2023
   

8. Anti-lung Cancer Marine Compounds: A Review

   Lung cancer is one of the most common and lethal cancers in human beings. Lung cancer has been divided into two major types: small cell lung cancer...

   Mohammad Reza Miri, Afshin Zare, ... Amin Tamadon in Therapeutic Innovation & Regulatory Science

   Article 13 January 2022
   

9. Design and optimization various formulations of PEGylated niosomal nanoparticles loaded with phytochemical agents: potential anti-cancer effects against human lung cancer cells

   Background

   Phytochemicals and their derivatives are good options to improve treatment efficiency in cancer patients. Artemisinin (ART) and metformin...

   Rasoul Shahbazi, Davoud Jafari-Gharabaghlou, ... Nosratollah Zarghami in Pharmacological Reports

   Article 01 March 2023
   

10. Tanshinone IIA targeting cell signaling pathways: a plausible paradigm for cancer therapy

    Natural compounds originating from plants offer a wide range of pharmacological potential and have traditionally been used to treat a wide range of...

    Syed Sahajada Mahafujul Alam, Arijit Samanta, ... Mehboob Hoque in Pharmacological Reports

    Article 13 July 2023
    

11. Gastric cancer and mesenchymal stem cell-derived exosomes: from pro-tumorigenic effects to anti-cancer vehicles

    Gastric cancer (GC) is one of the most prevalent malignancies in the world, with a high mortality rate in both women and men. Conventional...

    Maryam Dolatshahi, Ahmad Reza Bahrami, ... Maryam M. Matin in Archives of Pharmacal Research

    Article 27 December 2023
    

12. Trilaciclib for the reduction of chemotherapy-induced myelosuppression in the management of extensive-stage small cell lung cancer: a profile of its use

    Trilaciclib (COSELA™) is a transient inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6) that is approved in the USA to decrease the incidence of...

    Esther S. Kim, Susan J. Keam in Drugs & Therapy Perspectives

    Article 25 January 2022

13. Cytotoxic pathways activated by multifunctional thiosemicarbazones targeting sigma-2 receptors in breast and lung carcinoma cells

    Background

    Multifunctional thiosemicarbazones (TSCs) able to bind sigma receptors and chelate metals are considered as a promising avenue for the...

    Joanna Kopecka, Alessandra Barbanente, ... Carmen Abate in Pharmacological Reports

    Article Open access 05 October 2023
    

14. Pharmacogenomics and Cancer Treatment

    Somatic and germline genetic variations are two types of interindividual variations affecting drug response in cancer treatment. Pharmacogenomics...

    Ranjana Nagi, Jeeyun A. Kim, ... Christine Y. Lu in Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy

    Reference work entry 2023
    

15. Design, Synthesis and Biological Evaluation of Amide Derivatives of Thiazolo[5,4-d]Pyrimidines as Cytotoxicity Agents for Human Cancer Cell Lines

    We have designed and synthesized a new series of amide derivatives of thiazolo[5,4- d ]pyrimidines ( 10a-j ) and their structures were characterized by ¹ H...

    V. Balaraju, E. Laxminarayana, S. Kalyani in Pharmaceutical Chemistry Journal

    Article 01 November 2023
    

16. Mechanisms of resistance to chemotherapy in non-small cell lung cancer

    Non-small cell lung cancer (NSCLC), which represents 80–85% of lung cancer cases, is one of the leading causes of human death worldwide. The majority...

    Hye-Young Min, Ho-Young Lee in Archives of Pharmacal Research

    Article 19 February 2021
    

17. The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer

    In this article, we focus on the reimbursement process, and as an example, characterize the time to reimbursement of pembrolizumab , a PD-1 immune...

    Sarah Sharman Moser, Frank Tanser, ... Josie Solomon in Journal of Pharmaceutical Policy and Practice

    Article Open access 16 February 2023

18. A Comprehensive Nomogram Combining CT Imaging with Clinical Features for Prediction of Lymph Node Metastasis in Stage I–IIIB Non-small Cell Lung Cancer

    Objective

    The status of lymph node metastasis (LNM) is highly correlated with the recurrence and survival outcomes of patients with lung cancer. Thus,...

    **ngxing Zheng, **g**g Shao, ... Feng Feng in Therapeutic Innovation & Regulatory Science

    Article 26 October 2021
    

19. Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers

    Pralsetinib (PRL) is a selective Rearranged during Transfection (RET) inhibitor, developed by Blueprint Medicines Corporation for the treatment of...

    Faraat Ali, Kumari Neha, Garima Chauhan in Archives of Pharmacal Research

    Article 22 May 2022
    

20. Lung Cancer-Targeted [¹³¹I]-Iodoshikonin as Theranostic Agent: Radiolabeling, In Vivo Pharmacokinetics and Biodistribution

    Shikonin has been reported to exhibit high affinity toward lung cells and recited to inhibit the migration and invasion of lung cancer cells and...

    Adli A. Selim, M. A. Motaleb, Hend A. Fayez in Pharmaceutical Chemistry Journal

    Article 11 February 2022